2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2712

Intracellular O-Glc-Nac Alterations in Mononuclear Blood Cell of Rheumatoid Arthritis Patients
Abstract Number: 904

Intracerebroventricular Tweak (TNF-like weak inducer of apoptosis) Induces Depressive-like Behavior and Cognitive Dysfunction in Non-Autoimmune Mice
Abstract Number: 887

Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients
Abstract Number: 3000

Intrinsic Gene Expression Subset Predicts Improvement in Systemic Sclerosis Patients during Dasatinib (SprycelTM) Therapy
Abstract Number: 271

Investigating an Auto-Inflammatory Component of COPD That Contributes to Progressive Decline in Lung Function Despite Smoking Cessation
Abstract Number: 517

Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis
Abstract Number: 3107

Investigating the Ameliorating Effect of Pregnancy on Rheumatoid Arthritis Using Whole Transcriptome Analysis
Abstract Number: 298

Investigating the Pathogenic Role of ER Stress Pathway Activation in the Idiopathic Inflammatory Myopathies (IIM): Skeletal Muscle Cells As a Source of Cytokines (Myokines)
Abstract Number: 306

Investigating the Pathogenic Role of ER Stress Pathways in the Idiopathic Inflammatory Myopathies (IIM): Interrogating the Role of Micro-RNA 133a As an Important Regulator of ER Stress Activation
Abstract Number: 1362

Investigating the Role of Dendritic Cell Maturation & T Cell Activation within the Inflamed Synovium in Rheumatoid Arthritis
Abstract Number: 715

Investigating the Role of Vitamin D in Patients with SLE
Abstract Number: 24

Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease
Abstract Number: 2296

Investigation of Environmental Associations of Fibromyalgia Pain Using Twitter Content Analysis
Abstract Number: 257

Investigation of the Arterial Stiffness and Associated Factors in Patients with Familial Mediterranean Fever
Abstract Number: 1212

Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].